Voyager Therapeutics (NASDAQ:VYGR) Shares Down 1.1%

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) shares traded down 1.1% during mid-day trading on Tuesday . The stock traded as low as $8.07 and last traded at $8.15. 97,338 shares traded hands during trading, a decline of 90% from the average session volume of 934,279 shares. The stock had previously closed at $8.24.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. StockNews.com raised Voyager Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, March 9th. Wells Fargo & Company upgraded Voyager Therapeutics from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $9.00 to $14.00 in a report on Tuesday, January 2nd. Guggenheim began coverage on Voyager Therapeutics in a report on Tuesday, March 26th. They issued a "buy" rating and a $22.00 price objective for the company. Citigroup began coverage on Voyager Therapeutics in a report on Thursday, March 7th. They issued a "buy" rating and a $16.00 price objective for the company. Finally, HC Wainwright began coverage on Voyager Therapeutics in a report on Tuesday, March 19th. They issued a "buy" rating and a $30.00 price objective for the company. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $19.33.

Voyager Therapeutics Stock Down 3.2 %

The firm has a fifty day moving average price of $8.79 and a two-hundred day moving average price of $7.95. The stock has a market capitalization of $433.31 million, a P/E ratio of 2.58 and a beta of 0.96.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share for the quarter, beating the consensus estimate of ($0.59) by $1.84. Voyager Therapeutics had a return on equity of 63.89% and a net margin of 52.93%. The firm had revenue of $90.06 million during the quarter, compared to the consensus estimate of $4.95 million. Sell-side analysts anticipate that Voyager Therapeutics, Inc. will post -1.64 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Voyager Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Kestra Advisory Services LLC purchased a new stake in shares of Voyager Therapeutics during the third quarter valued at $980,000. Ritholtz Wealth Management boosted its position in shares of Voyager Therapeutics by 11.8% during the fourth quarter. Ritholtz Wealth Management now owns 19,759 shares of the company's stock valued at $167,000 after buying an additional 2,089 shares during the last quarter. Alps Advisors Inc. purchased a new stake in shares of Voyager Therapeutics during the third quarter valued at $294,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Voyager Therapeutics during the fourth quarter valued at $43,000. Finally, Aigen Investment Management LP purchased a new stake in shares of Voyager Therapeutics during the third quarter valued at $109,000. 48.03% of the stock is currently owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.